Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03861338 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03861338 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 11 participants.
The verdict
NCT03861338, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The proposed study is a 12-week, open-label pilot study of sublocade (extended-release burprenorphine, BXR) as treatment for opiate use disorder (OUD) testing positive for Highly Potent Synthetic Opioids (HPSO). The investigators plan to enroll 10 participants into the study.
Interventions
- DRUG Sublocade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2020-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03861338
The ClinicalTrials.gov registry entry for NCT03861338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sublocade is the first listed.
NCT03861338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03861338 about?
NCT03861338 is a clinical study titled "An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder". The proposed study is a 12-week, open-label pilot study of sublocade (extended-release burprenorphine, BXR) as treatment for opiate use disorder (OUD) testing positive for Highly Potent Synthetic Opioids (HPSO). The investigators plan to enroll 10 participants into the study.
What is the current status of trial NCT03861338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-03-01. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT03861338?
The interventions under investigation include: Sublocade (DRUG).
Who is sponsoring clinical trial NCT03861338?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.